Processing, please wait...
4 videos 13 badges
[THRESHOLD] videos


United States

George Kroumpouzos, MD, Ph.D., FAAD, Director of GK Dermatology, is a Clinical Associate Professor of Dermatology at Alpert Medical School, Brown University. He has served as Professor of Dermatology (Collaborator) at Jundiai Medical School, Brazil, and Instructor of Dermatology at Harvard Medical School. He is certified by both American and European Boards of Dermatology. Dr. Kroumpouzos is a Board Member of the International Academy of Cosmetic Dermatology and the Canadian Board of Aesthetic Medicine. His expertise is in the fields of aesthetic/procedural dermatology, gynecologic/obstetric dermatology, and disorders of pigmentation. Dr. Kroumpouzos is Associate Editor of the International Journal of Women’s Dermatology, Dermatologic Therapy, and Frontiers in Medicine, and Editor of Clinics in Dermatology. He is a member of the Council of Science Editors. He has published over 140 peer-reviewed publications and 40 book chapters. He is the Editor of 4 books including the definitive Text Atlas of Obstetric Dermatology and 2 monographs. Dr. Kroumpouzos has chaired expert panels at numerous national and international physician conferences. His research publications have been cited in announcements of the Dean of Alpert Medical School at Brown University. He is the recipient of several scholarships and awards, including awards by the International Union Against Cancer, New England Dermatologic Society, and the Dean’s Excellence in Teaching Award at Alpert Medical School of Brown University.

read more
add item add George KROUMPOUZOS

George KROUMPOUZOS's publications (79)

Nonmelanoma skin cancer in the setting of erosive pustular dermatosis of the scalp: A case series and comment on management implications.

Jul, 2022

Erosive pustular dermatosis of the scalp (EPDS) is an inflammatory cutaneous disorder typically affecting sun-damaged skin of mature individuals. Clinical features of EPDS include sterile pustules and chronic crusted erosions that can be hyperkeratotic and lead to scarring alopecia, atrophy, and telangiectasia. While the condition occurs on sun-damaged skin, a relationship with non-melanoma skin cancer (NMSC) has not been investigated. read more

Dermatologic therapy

Hormonal Therapies in the Management of Acne Vulgaris.

Jun, 2022

Acne vulgaris is a multifactorial chronic disorder of the pilosebaceous unit. Established treatments include topical retinoids, antibiotics in mild cases, and oral antibiotics and isotretinoin in moderate to severe cases. Anti-androgens and other hormonal therapies constitute another group of drugs in the armamentarium of acne management. These can be used in patients who do not respond to the aforementioned treatments or when other systemic drugs cannot be tolerated. Recent approval of topical androgen receptor blocker is an additional armamentarium for the management of acne. Considering limited systemic exposure and good efficacy, it has potential for wide usage in patients with acne. In this article, we critically review currently available hormonal treatment options based on published literature search of an electronic database (MEDLINE/PubMed) performed through June 2021. J Drugs Dermatol. 2022;21(6):618-623. doi:10.36849/JDD.6494. read more

Journal of drugs in dermatology : JDD

Rosacea management: A comprehensive review.

May, 2022

Rosacea is a chronic cutaneous disorder affecting primarily the face, characterized by erythema, transient or persistent, telangiectasia, and inflammatory lesions including papulo-pustules and swelling. The essential component of the disease is the persistent erythema of facial skin. Episodes of flushing (acute-subacute intermittent vasodilation) are common. Swelling and erythema of the nose along with dilatation of the pilosebaceous poral orifices, known as rhinophyma, can be noted in chronic cases. Rosacea affects up to 10% of the world population and is especially noted in fair-skinned individuals aged 35-50. Women are affected more often than men. Several treatment modalities including topical medications, systemic drugs, lasers, and light-based therapies have been used for the management of rosacea with variable results. Topical medications such as azelaic acid, metronidazole, and sulfacetamide/sulfur, oral antibiotics such as tetracyclines, and oral retinoids alone or, most commonly, in combination form the mainstay of treatment. Light therapies such as intense pulsed light and pulsed dye laser are best used for the erythemato-telangiectatic type. Topical brimonidine, oxymetazoline, ivermectin, tacrolimus, pimecrolimus, low-dose modified-release tetracyclines and botulinum toxin are the new additions to the therapeutic armamentarium. This article provides a comprehensive review of the various therapies used for rosacea. read more

Journal of cosmetic dermatology
Load more  

George KROUMPOUZOS's scientific societies (6)